| Patient | Mumtaz Mahal |
|---|---|
| Date of birth | 1988-04-27 |
| Identifiers | MRN HR-RE006-SYN; SSN (made up) 000-06-7184 |
| Document date | 2026-11-01 |
| Author | Farzana Qureshi-Lindholm, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
First prenatal visit at 13 weeks in a fourteenth pregnancy: dating and nuchal translucency scan, prenatal tests, and a high-risk plan. Concerns: Pregnant again soon after her last baby; tired and breathless on stairs, and unsure how far along she is; She has lost six children and wants to do everything possible for this baby and to be well enough for the children she has; Her family may travel again during the pregnancy and she wants to know when and how she can travel safely. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-06 | active | S |
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day | One tablet every other morning with water or orange juice, apart from tea and calcium | Oral route | 2026-01-06 to 2026-02-03 | completed | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime until delivery | Oral route | 2026-01-06 | active | S |
| Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily for 5 days | One capsule twice daily with food for 5 days | Oral route | 2026-03-24 to 2026-03-29 | completed | S |
| Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses) | Single infusion; two doses in total, four weeks apart | Intravenous route | 2026-02-03 to 2026-02-03 | completed | S |
| Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (second of two doses) | Single infusion; two doses in total, four weeks apart | Intravenous route | 2026-03-03 to 2026-03-03 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| First-trimester ultrasound for dating and nuchal translucency: single live intrauterine fetus, crown-rump length 72 mm (13 weeks 2 days), nuchal translucency 1.7 mm, nasal bone present; placenta posterior; no structural abnormality seen | 2026-01-06 to 2026-01-06 | completed | S |
| Detailed fetal anatomy ultrasound at 21 weeks 2 days: single fetus, normal anatomy, estimated weight 410 g; placenta posterior and fundal, lower edge more than 5 cm from the internal os; no placental lacunae, normal retroplacental clear zone and myometrial thickness; normal amniotic fluid | 2026-03-03 to 2026-03-03 | completed | S |
| Third-trimester growth ultrasound at 34 weeks 2 days: cephalic presentation, estimated weight 2380 g (about the 45th centile), normal amniotic fluid, placenta posterior fundal | 2026-06-02 to 2026-06-02 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-01-06 | Influenza vaccine, 2025-2026 season, given in pregnancy | completed | S |
| 2026-04-14 | Tdap vaccine in pregnancy, 27 weeks | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1613 to 1630 | Thirteen births between 1613 and 1630, the last in April 1630, while travelling with the court | D (CLM-0006, CLM-0005) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| natural daughter | Eldest daughter died of smallpox in 1616, aged three | 3 | D (CLM-0007) |
| natural son | A son died in infancy in 1621; cause not recorded in the cited source | D (CLM-0007) | |
| natural son | A son died soon after birth in 1622; cause not recorded in the cited source | D (CLM-0007) | |
| natural daughter | A daughter died of smallpox in 1628, aged seven | 7 | D (CLM-0007) |
| natural son | A son died in 1628 at about eighteen months; cause not recorded in the cited source | D (CLM-0007) | |
| natural son | A son died in infancy in 1629; cause not recorded in the cited source | D (CLM-0007) |
| Concern | Status | Evidence |
|---|---|---|
| Pregnant again soon after her last baby; tired and breathless on stairs, and unsure how far along she is | active | S |
| She has lost six children and wants to do everything possible for this baby and to be well enough for the children she has | active | S |
| Her family may travel again during the pregnancy and she wants to know when and how she can travel safely | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 11.8 on 2026-06-02; MCV [Entitic mean volume] in Red Blood Cells by Automated count 76 on 2026-01-06; Leukocytes [#/volume] in Blood by Automated count 8.6 on 2026-01-06; Platelets [#/volume] in Blood by Automated count 228 on 2026-06-02; Ferritin [Mass/volume] in Serum or Plasma 110 on 2026-04-14; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-01-06; Fetal Crown Rump length US 72 on 2026-01-06; Fetal nuchal translucency measured by US 1.7 on 2026-01-06; Total score [EPDS] 5 on 2026-06-02; Fetal Body weight estimated by US 2380 on 2026-06-02; Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g glucose PO 128 on 2026-04-14 [S]
Strengths and supports: Supports: a large household, her eldest daughter, and a close woman friend who travels with her [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12 | active | confirmed | O09.529 | S — Synthetic modern prenatal care anchored to her documented fourteenth pregnancy; the dates are synthetic. |
| Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living children | active | confirmed | O09.40 | S — Synthetic modern problem anchored to her documented thirteen earlier births. |
| Short interpregnancy interval: conception about five and a half months after her last birth | active | confirmed | O09.899 | S — Synthetic modern problem anchored to the documented fourteen months between her last two births. |
| Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mL | active | confirmed | O99.019 | S — Synthetic finding; repeated pregnancies close together deplete iron. It echoes no documented diagnosis. |
| Acute cystitis in pregnancy at 24 weeks: dysuria and frequency, no fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; treated and resolved | resolved | confirmed | O23.12 | S — Synthetic intercurrent infection at an unscheduled visit; common in pregnancy and in multiparous women. It echoes no documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-06 | Hemoglobin [Mass/volume] in Blood | 10.1 | g/dL | 11-15 g/dL | Low | S |
| 2026-01-06 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 76 | fL | 80-100 fL | Low | S |
| 2026-01-06 | Leukocytes [#/volume] in Blood by Automated count | 8.6 | 10*3/uL | 4-13 10*3/uL | Normal | S |
| 2026-01-06 | Platelets [#/volume] in Blood by Automated count | 245 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-01-06 | Ferritin [Mass/volume] in Serum or Plasma | 9 | ng/mL | 30-150 ng/mL | Low | S |
| 2026-01-06 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | <=5.7% | Normal | S |
| 2026-01-06 | Fetal Crown Rump length US | 72 | mm | Consistent with 13 weeks 2 days; used for dating because her last period is not known | Normal | S |
| 2026-01-06 | Fetal nuchal translucency measured by US | 1.7 | mm | <=3.5 mm | Normal | S |
| 2026-01-06 | Total score [EPDS] | 8 | {score} | S | ||
| 2026-02-03 | Hemoglobin [Mass/volume] in Blood | 10.3 | g/dL | 10.5-15 g/dL | Low | S |
| 2026-02-03 | Ferritin [Mass/volume] in Serum or Plasma | 12 | ng/mL | 30-150 ng/mL | Low | S |
| 2026-03-03 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 10.5-15 g/dL | Normal | S |
| 2026-03-03 | Ferritin [Mass/volume] in Serum or Plasma | 96 | ng/mL | 30-150 ng/mL | Normal | S |
| 2026-03-03 | Fetal Body weight estimated by US | 410 | g | About the 50th centile for 21 weeks | Normal | S |
| 2026-04-14 | Hemoglobin [Mass/volume] in Blood | 11.4 | g/dL | 10.5-15 g/dL | Normal | S |
| 2026-04-14 | Ferritin [Mass/volume] in Serum or Plasma | 110 | ng/mL | 30-150 ng/mL | Normal | S |
| 2026-04-14 | Platelets [#/volume] in Blood by Automated count | 232 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-14 | Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g glucose PO | 128 | mg/dL | <=139 mg/dL | Normal | S |
| 2026-04-14 | Total score [EPDS] | 6 | {score} | S | ||
| 2026-06-02 | Hemoglobin [Mass/volume] in Blood | 11.8 | g/dL | 11-15 g/dL | Normal | S |
| 2026-06-02 | Platelets [#/volume] in Blood by Automated count | 228 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-02 | Total score [EPDS] | 5 | {score} | S | ||
| 2026-06-02 | Fetal Body weight estimated by US | 2380 | g | About the 45th centile for 34 weeks | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-06 | Body height | 157 | cm | S |
| 2026-01-06 | Body weight | 58.6 | kg | S |
| 2026-01-06 | Body mass index (BMI) [Ratio] | 23.8 | kg/m2 | S |
| 2026-01-06 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-01-06 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-01-06 | Heart rate | 84 | /min | S |
| 2026-01-06 | Respiratory rate | 14 | /min | S |
| 2026-01-06 | Body temperature | 36.7 | Cel | S |
| 2026-01-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-02-03 | Body height | 157 | cm | S |
| 2026-02-03 | Body weight | 59.8 | kg | S |
| 2026-02-03 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 2026-02-03 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-02-03 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-02-03 | Heart rate | 86 | /min | S |
| 2026-02-03 | Respiratory rate | 14 | /min | S |
| 2026-02-03 | Body temperature | 36.6 | Cel | S |
| 2026-02-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-03-03 | Body height | 157 | cm | S |
| 2026-03-03 | Body weight | 61.9 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 25.1 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 88 | /min | S |
| 2026-03-03 | Respiratory rate | 14 | /min | S |
| 2026-03-03 | Body temperature | 36.7 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-03-24 | Body height | 157 | cm | S |
| 2026-03-24 | Body weight | 62.6 | kg | S |
| 2026-03-24 | Body mass index (BMI) [Ratio] | 25.4 | kg/m2 | S |
| 2026-03-24 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-03-24 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-03-24 | Heart rate | 92 | /min | S |
| 2026-03-24 | Respiratory rate | 16 | /min | S |
| 2026-03-24 | Body temperature | 37.1 | Cel | S |
| 2026-03-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-14 | Body height | 157 | cm | S |
| 2026-04-14 | Body weight | 64.6 | kg | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 26.2 | kg/m2 | S |
| 2026-04-14 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-04-14 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-04-14 | Heart rate | 86 | /min | S |
| 2026-04-14 | Respiratory rate | 16 | /min | S |
| 2026-04-14 | Body temperature | 36.7 | Cel | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-06-02 | Body height | 157 | cm | S |
| 2026-06-02 | Body weight | 68 | kg | S |
| 2026-06-02 | Body mass index (BMI) [Ratio] | 27.6 | kg/m2 | S |
| 2026-06-02 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-06-02 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-06-02 | Heart rate | 88 | /min | S |
| 2026-06-02 | Respiratory rate | 16 | /min | S |
| 2026-06-02 | Body temperature | 36.8 | Cel | S |
| 2026-06-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-01-06 | First prenatal visit at 13 weeks in a fourteenth pregnancy: dating and nuchal translucency scan, prenatal tests, and a high-risk plan | finished | S |
| 2026-02-03 | Prenatal visit at 17 weeks, with maternal-fetal medicine consultation | finished | S |
| 2026-03-03 | Prenatal visit at 21 weeks with the anatomy scan and placental location | finished | S |
| 2026-04-14 | Prenatal visit at 27 weeks: glucose challenge, blood count, and Tdap | finished | S |
| 2026-06-02 | Prenatal visit at 34 weeks: growth scan, postpartum hemorrhage risk assessment, delivery plan, and contraception counseling | finished | S |
| 2026-03-24 | Same-day sick visit for painful, frequent urination at 24 weeks | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| First prenatal visit: dating and nuchal translucency scan; blood count, ferritin, blood group and antibody screen, rubella immunity, hepatitis B surface antigen, HIV, syphilis, and hepatitis C tests; urine culture for asymptomatic bacteriuria; hemoglobin electrophoresis for microcytosis; hemoglobin A1c as an early diabetes screen; influenza vaccine; folic acid | completed | GL-USPSTF-AB, GL-CDC-PREGVAX, GL-ACOG-AMA-2022 | S |
| Aneuploidy screening offered, with diagnostic testing available: cell-free DNA and the nuchal translucency measurement today, or chorionic villus sampling or amniocentesis; she chose cell-free DNA | completed | GL-ACOG-ANEU-2020, GL-ACOG-AMA-2022 | S |
| Maternal-fetal medicine consultation for a fourteenth pregnancy at 37 with a short interpregnancy interval and anemia: surveillance, anemia treatment, placental assessment, delivery timing and place, and postpartum hemorrhage planning | completed | GL-ACOG-AMA-2022, GL-ACOG-PPH-2017 | S |
| Iron deficiency anemia: ferrous sulfate 325 mg every other day; repeat blood count and ferritin in four weeks, with intravenous iron in the second trimester if she cannot tolerate oral iron or the hemoglobin does not rise; aim for hemoglobin of 11 g/dL or more before delivery | completed | GL-ACOG-ANEMIA-2021 | S |
| Preeclampsia prevention: aspirin 81 mg at bedtime from 13 weeks until delivery for two moderate risk factors (age 35 or older and a previous adverse pregnancy outcome); blood pressure and urine protein at every visit | completed | GL-USPSTF-ASA-2021 | S |
| Detailed anatomy scan at 20 to 22 weeks with placental location; if the placenta is low-lying or covers the cervix, a repeat scan at 32 weeks and assessment for placenta accreta spectrum | completed | GL-ACOG-AMA-2022, GL-ACOG-PAS-2018 | S |
| Gestational diabetes: hemoglobin A1c today because she is of South Asian heritage with a BMI of 23 or more; one-hour glucose challenge at 24 to 28 weeks | completed | GL-ACOG-GDM-2018 | S |
| Travel: travel is reasonable until about 36 weeks if the pregnancy stays uncomplicated; on long journeys walk every one to two hours, drink plenty, and wear compression stockings; carry her prenatal record; find maternity care where she stays; stay near the delivery hospital from 36 weeks | completed | GL-ACOG-TRAVEL-2018 | S |
| Postpartum hemorrhage risk assessment at intake and again in the third trimester and on admission for birth (grand multiparity and anemia raise her risk); delivery planned in a hospital with a blood bank, anesthesia, and an operating theatre | completed | GL-ACOG-PPH-2017, GL-WHO-PPH-2012 | S |
| Mood: EPDS in each trimester, with support for the grief of having lost several children | completed | GL-ACOG-MH-2023 | S |
| Postpartum hemorrhage plan for birth: induction at 39 weeks in hospital; type and screen and blood count on admission; two large-bore intravenous lines; avoid prolonged labor, with timely assessment of progress; oxytocin 10 units after birth as active management of the third stage; quantitative blood loss; tranexamic acid 1 g intravenously within 3 hours of birth if hemorrhage is diagnosed, with a second 1 g dose if bleeding continues after 30 minutes; second-line uterotonics, a uterine balloon, and the massive transfusion protocol ready | completed | GL-ACOG-PPH-2017, GL-WHO-PPH-2012, GL-WHO-TXA-2017, GL-WOMAN-2017, GL-ACOG-AMA-2022 | S |
| Contraception and interpregnancy interval, on her own terms: options explained (implant, hormonal or copper IUD, progestin-only pill, lactational amenorrhea, and permanent methods); she chose an etonogestrel implant before discharge after the birth and plans to wait at least 18 to 24 months before any future pregnancy | completed | GL-ACOG-IPC-2019, GL-CDC-USMEC-2024 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Hemoglobin at least 11 g/dL with replete iron stores before delivery | 2026-06-02 | completed | Hemoglobin 11.8 g/dL and ferritin 110 ng/mL after two doses of intravenous iron | S |
| An informed choice about aneuploidy screening by 14 weeks | 2026-02-03 | completed | Chose cell-free DNA (low risk) with the nuchal translucency scan (1.7 mm); declined diagnostic testing | S |
| Blood pressure below 140/90 mmHg with aspirin taken nightly from 13 weeks | 2026-07-12 | active | Blood pressure 104/62 to 112/70 mmHg throughout; aspirin taken nightly | S |
| A written delivery and postpartum hemorrhage plan agreed by 36 weeks, with birth planned in a hospital with a blood bank and operating theatre | 2026-06-02 | completed | Plan agreed at 34 weeks: induction at 39 weeks at the hospital, oxytocin after birth, quantitative blood loss, and tranexamic acid ready | S |
| A postpartum contraception choice and a plan for the interval before any future pregnancy, made on her own terms before delivery | 2026-06-02 | completed | Chose an etonogestrel implant before discharge after the birth; plans at least 18 to 24 months before any future pregnancy | S |